Global X Genomics & Biotechnology ETF (GNOM) Stock Forecast
Alert
Its only available to paid users.
N/A
Based on the Global X Genomics & Biotechnology ETF stock forecast from 0 analysts, the average analyst target price for Global X Genomics & Biotechnology ETF is not available over the next 12 months. Global X Genomics & Biotechnology ETF’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Global X Genomics & Biotechnology ETF is Very Bearish, which is based on 0 positive signals and 6 negative signals. At the last closing, Global X Genomics & Biotechnology ETF’s stock price was USD 9.69. Global X Genomics & Biotechnology ETF’s stock price has changed by -0.92% over the past week, -14.17% over the past month and -19.80% over the last year.
No recent analyst target price found for Global X Genomics & Biotechnology ETF
No recent average analyst rating found for Global X Genomics & Biotechnology ETF
Company Overview Global X Genomics & Biotechnology ETF
The fund invests at least 80% of its total assets in the securities of the underlying index. The underlying index is designed to provide exposure to exchange-listed companies that are positioned to benefit from further advances in the field of genomic science and biotechnology, as well as applications thereof (collectively, Genomics & Biotechnology Companies), as defined by Solactive AG, the provider of the underlying index. The fund is non-diversified. Read Less
The fund invests at least 80% of its total assets in the securities of the underlying index. The underlying index is designed to provide exposure to exchange-listed companies that are positioned to benefit from further advances in the field of genomic science and biotechnology, a...Read More
N/A
N/A
0
N/A
USD
USA
05/04/2019
Solactive Genomics USD
N/A
0.50 %
Adjusted Closing Price for Global X Genomics & Biotechnology ETF (GNOM)
Loading...
Unadjusted Closing Price for Global X Genomics & Biotechnology ETF (GNOM)
Loading...
Share Trading Volume for Global X Genomics & Biotechnology ETF Shares
Loading...
Compare Performance of Global X Genomics & Biotechnology ETF Shares
Frequently Asked Questions About Global X Genomics & Biotechnology ETF (GNOM) Stock
Stock Target Advisor's fundamental analysis for Global X Genomics & Biotechnology ETF's stock is Very Bearish.
Unfortunately we do not have enough data on GNOM's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on GNOM's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on GNOM's stock to indicate if its overvalued.
The last closing price of GNOM's stock was USD 9.69.
The most recent market capitalization for GNOM is USD 0.10B.
Unfortunately we do not have enough analyst data on GNOM's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Global X Genomics & Biotechnology ETF's stock.
As per our most recent records Global X Genomics & Biotechnology ETF has 0 Employees.
Sorry we do not have any infomation available on Global X Genomics & Biotechnology ETF's address.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
There is nothing we particularly like
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Below median total returns
The company has under performed its peers on annual average total returns in the past 5 years.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for GNOM !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Stocktwits
